Research and development of NASH new drugs, the new company landed on the NASDAQ.

Founded in 2015 by entrepreneur Rich Heyman and Professor Ron Evans of the Salk Institute, Metacrine focuses on the development of innovative treatments for liver, gastrointestinal and metabolic diseases, having previously completed multiple rounds of financing.
will use this round of financing to advance clinical trials of both met409 and MET642, a physiotherapist (FXR) astigtor for the treatment of non-alcoholic fatty hepatitis (NASH).
Photo Source: Metacrine Website According to Metalcrine, the MET409 project recently completed a Phase I clinical trial of 58 patients, and results released last month show that after 12 weeks of treatment, MET409 reduced liver fat content and NASH biomarkers improved.
these results helped the MET409 program gain fast-track eligibility from the FDA last month.
Metacrine expects to conduct phase 2 clinical trials of MET409 in the first half of 2021 using a combined treatment for NASH with anti-diabetic drugs.
addition to met409, Metacrine's second drug candidate, MET642, was also completed in Phase 1 clinical trials.
and will soon conduct Phase 2 clinical trials.
NASH is a chronic, aggressive liver disease caused by the accumulation of fat in the liver, which causes inflammation in the liver.
can lead to liver fibrosis, and if left untreated, NASH patients may develop cirrhosis, liver failure, and even liver cancer.
despite the large population of NASH patients, the FDA has not yet approved NASH drugs for the market, so the relevant drug research and development companies have also received capital attention.
this year, companies such as Aligos Therapeutics and Lipidio Pharmaceuticals have completed different rounds of financing.
: s1. Metacrine Announces Pricing of Initial Public Offering. Retrieved September 16, 2020, from.